Hims & Hers Health is facing increasing regulatory pressure from US regulators, including an investigation by the FDA.[2] In September, it came under FDA scrutiny for alleged deceptive advertising.[2] The company recently dropped a plan to offer a compounded version of Wego's diet pill, which it wanted to sell for $49 the first month and $99 a month thereafter.[1] This decision came two days after the new product announcement and one day after the FDA announcement.[1] Hims changed its strategy and began offering personalized versions of semaglutide, the active ingredient in Novo Nordisk's popular drug Wegovy.[2] The company named Deb Autor as its first chief policy officer, who will be the key person for the firm's regulatory and political relations.[2] Shares of Hims & Hers Health are in a significant downtrend and are trading at $37.03, down sharply from levels above $50 in recent weeks.[2]